AEON Biopharma Reports Q2 2026 Financial Results

What Happened
AEON Biopharma, Inc. announced its financial results for the quarter ended June 30, 2026, via a press release issued on August 12, 2026. The press release is furnished as Exhibit 99.1 to the company's Form 8-K. On the same date AEON made a corporate presentation available in its investor relations section, which is furnished as Exhibit 99.2 and may be used by management in future investor meetings. The filing was signed by President and CEO Robert Bancroft.

Key Details

• Date of filing: August 12, 2026; quarter reported: Q2 ended June 30, 2026.
• Press release reporting Q2 results: furnished as Exhibit 99.1 to the Form 8-K.
• Corporate Presentation: furnished as Exhibit 99.2, available on AEON’s investor relations website; includes a “Forward-Looking Statements” slide.
• The information furnished under Items 2.02 and 7.01 (including Exhibits 99.1 and 99.2) is furnished, not “filed,” and therefore is not subject to Section 18 liabilities unless expressly incorporated by reference elsewhere.

Why It Matters
This 8-K formally notifies investors that AEON has released its quarterly financial results and supporting investor materials. Retail investors should review Exhibit 99.1 (the press release) and Exhibit 99.2 (the corporate presentation) for the specific revenue, expense, and operational figures and for any forward-looking statements or guidance. The filing’s furnished (not filed) status limits certain legal exposures but does not change the value of the financial and operational details provided for evaluating AEON’s recent performance.